3-aminobenzamide has been researched along with temozolomide in 8 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 3 (37.50) | 18.2507 |
| 2000's | 4 (50.00) | 29.6817 |
| 2010's | 1 (12.50) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Almassy, R; Calvert, AH; Curtin, NJ; Golding, BT; Griffin, RJ; Hostomsky, Z; Maegley, K; Newell, DR; Srinivasan, S; White, AW | 1 |
| Newlands, ES; Porteous, JK; Wedge, SR | 1 |
| Benincasa, E; Bonmassar, E; Faraoni, I; Franco, D; Graziani, G; Lacal, PM; Tentori, L | 1 |
| Bonmassar, E; Franco, D; Graziani, G; Levati, L; Roy, R; Serafino, A; Tentori, L; Turriziani, M | 1 |
| Graziani, G; Navarra, P; Portarena, I; Scerrati, M; Tentori, L; Torino, F | 1 |
| Ali-Osman, F; Bigner, DD; Cheng, CL; Dolan, ME; Friedman, HS; Johnson, SP; Keir, ST; Li, H; Modrich, P; Quinn, JA; Salzman, AL; Szabo, C | 1 |
| Bedikian, AY; Cain, S; Glass, MR; Homsi, J; Hwu, P; Hwu, WJ; Kim, KB; Papadopoulos, NE; Rudewicz, P; Vernillet, L | 1 |
| Ali-Osman, F; Angelica Selim, M; Augustine, CK; Friedman, HS; Padussis, JC; Pruitt, SK; Toshimitsu, H; Tyler, DS; Yoo, JS; Yoshimoto, Y | 1 |
1 trial(s) available for 3-aminobenzamide and temozolomide
| Article | Year |
|---|---|
A phase IB trial of intravenous INO-1001 plus oral temozolomide in subjects with unresectable stage-III or IV melanoma.
Topics: Administration, Oral; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Diseases; Chemical and Drug Induced Liver Injury; Dacarbazine; DNA Mismatch Repair; Drug Administration Schedule; Female; Humans; Indoles; Infusions, Intravenous; Male; Melanoma; Middle Aged; Neoplasm Proteins; Poly (ADP-Ribose) Polymerase-1; Poly(ADP-ribose) Polymerase Inhibitors; Poly(ADP-ribose) Polymerases; Temozolomide | 2009 |
7 other study(ies) available for 3-aminobenzamide and temozolomide
| Article | Year |
|---|---|
Resistance-modifying agents. 9. Synthesis and biological properties of benzimidazole inhibitors of the DNA repair enzyme poly(ADP-ribose) polymerase.
Topics: Antineoplastic Agents; Benzimidazoles; Crystallography, X-Ray; Dacarbazine; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Drug Synergism; Enzyme Inhibitors; Humans; Models, Molecular; Poly(ADP-ribose) Polymerase Inhibitors; Structure-Activity Relationship; Temozolomide; Topotecan; Tumor Cells, Cultured | 2000 |
3-aminobenzamide and/or O6-benzylguanine evaluated as an adjuvant to temozolomide or BCNU treatment in cell lines of variable mismatch repair status and O6-alkylguanine-DNA alkyltransferase activity.
Topics: Antineoplastic Agents, Alkylating; Benzamides; Carmustine; Dacarbazine; DNA Repair; Drug Screening Assays, Antitumor; Drug Synergism; Enzyme Inhibitors; Guanine; Humans; Neoplasms; Temozolomide; Tumor Cells, Cultured | 1996 |
Role of wild-type p53 on the antineoplastic activity of temozolomide alone or combined with inhibitors of poly(ADP-ribose) polymerase.
Topics: Antineoplastic Agents, Alkylating; Apoptosis; Benzamides; Dacarbazine; Enzyme Inhibitors; Guanine; HL-60 Cells; Humans; O(6)-Methylguanine-DNA Methyltransferase; Poly(ADP-ribose) Polymerase Inhibitors; Temozolomide; Tumor Suppressor Protein p53 | 1998 |
Treatment with temozolomide and poly(ADP-ribose) polymerase inhibitors induces early apoptosis and increases base excision repair gene transcripts in leukemic cells resistant to triazene compounds.
Topics: Antineoplastic Agents, Alkylating; Apoptosis; Benzamides; Dacarbazine; DNA Glycosylases; DNA Ligases; DNA Repair; Drug Interactions; Drug Resistance, Neoplasm; Enzyme Inhibitors; Guanine; Humans; Jurkat Cells; Leukemia; N-Glycosyl Hydrolases; Poly(ADP-ribose) Polymerase Inhibitors; RNA, Messenger; Temozolomide; Transcription, Genetic; Triazenes | 1999 |
Poly(ADP-ribose) polymerase inhibitor increases growth inhibition and reduces G(2)/M cell accumulation induced by temozolomide in malignant glioma cells.
Topics: Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Brain Neoplasms; cdc25 Phosphatases; Cell Cycle Proteins; Checkpoint Kinase 1; Dacarbazine; DNA Repair; Down-Regulation; Drug Interactions; Drug Resistance, Neoplasm; Drug Therapy, Combination; Enzyme Inhibitors; G2 Phase; Glioblastoma; Glioma; Humans; Mitosis; Poly (ADP-Ribose) Polymerase-1; Poly(ADP-ribose) Polymerases; Protein Kinases; Proteins; Temozolomide; Tumor Cells, Cultured; Tumor Suppressor Protein p53; Up-Regulation | 2002 |
Poly(ADP-ribose) polymerase-1 inhibition reverses temozolomide resistance in a DNA mismatch repair-deficient malignant glioma xenograft.
Topics: Animals; Antineoplastic Agents, Alkylating; Base Pair Mismatch; Dacarbazine; DNA Repair; Drug Resistance, Neoplasm; Indoles; Medulloblastoma; Mice; Mice, Inbred BALB C; Mice, Nude; Poly (ADP-Ribose) Polymerase-1; Poly(ADP-ribose) Polymerase Inhibitors; Temozolomide; Transplantation, Heterologous; Tumor Cells, Cultured | 2005 |
Inhibition of poly(ADP-ribose) polymerase enhances the effect of chemotherapy in an animal model of regional therapy for the treatment of advanced extremity malignant melanoma.
Topics: Alkylating Agents; Animals; Antineoplastic Combined Chemotherapy Protocols; Cell Line, Tumor; Dacarbazine; Disease Models, Animal; Extremities; Humans; In Vitro Techniques; Indoles; Melanoma; Poly(ADP-ribose) Polymerase Inhibitors; Rats; Rats, Nude; Severity of Illness Index; Temozolomide; Treatment Outcome | 2010 |